Omega-3 fatty acids are a prescription drug containing high-purity Omega-3 fatty acid ethyl ester, mainly composed of eicosapentaenoic acid ethyl ester (EPA-E) and docosahexaenoic acid ethyl ester (DHA-E).

1、 Drug name

1. Product Name: Lotriga Granular Capsules 2g

2. Common name: Omega-3 fatty acid ethyl ester

2、 Indications

1. Hyperlipidemia.

3、 Specifications and characteristics

1. Specification: Contains 2g of Omega-3 fatty acids per unit.

2. Appearance: Soft capsule, colorless to light yellow transparent, spherical with a diameter of about 4mm.

4、 Main components

Active ingredients: Each contains 2g of Omega-3 fatty acids (mainly composed of ethyl eicosapentaenoic acid and ethyl docosahexaenoic acid).

5、 Usage and dosage

1. Usually, adults take 2g each time, once a day, orally immediately after meals.

2. It can be increased to 2g twice a day according to the degree of triglyceride elevation.

6、 Dose adjustment

According to triglyceride levels, it can be increased from 2g once daily to 2g twice daily.

7、 Medication precautions

1. Before and after meals: It must be taken immediately after meals, and if taken on an empty stomach, it may cause malabsorption.

2. Usage: It should be swallowed whole and not chewed.

3. Missing service: Not clearly stated, it is recommended to follow the principle of regular replacement service.

4. Vomiting: Not explicitly stated. If vomiting occurs after taking medication, it is recommended to consult a doctor.

5. Monitoring requirements: Blood lipids should be checked regularly during medication, and if the efficacy is not significant, the medication should be discontinued; Regular monitoring of LDL cholesterol (which may increase) is necessary.

6. Life guidance: life habit improvement guidance should be given before medication, and the reduction of coronary heart disease risk factors such as hypertension, smoking, diabetes should be fully considered.

8、 Medication for special populations

1. Patients with high risk of bleeding (such as severe trauma, surgery, etc.): may promote bleeding and should be cautious.

2. Patients with liver dysfunction: It is recommended to undergo liver function tests (AST, ALT, etc.).

3. Pregnant women: Use only when the benefits of treatment outweigh the risks.

4. Breastfeeding women should weigh the benefits of treatment and breastfeeding before deciding whether to continue breastfeeding. Animal experiments have shown that drugs can enter breast milk.

5. Children: No clinical trials have been conducted for children.

9、 Adverse reactions

1. Serious side effects: liver function impairment, jaundice (frequency unknown); Atrial fibrillation and atrial flutter (frequency unknown, increased risk reported in foreign clinical trials).

2. Other common side effects (1-5%): diarrhea.

3. Other rare side effects (<1% or frequency unknown): rash, itching, high blood sugar, gout, dizziness, headache, abnormal taste, low blood pressure, nosebleeds, nausea, abdominal pain, belching, indigestion, gastroesophageal reflux, bloating, constipation, vomiting, gastrointestinal bleeding, elevated liver enzymes (AST, ALT), etc.

10、 Contraindications

1. Bleeding patients (such as hemophilia, capillary fragility, gastrointestinal ulcers, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.) may have difficulty stopping bleeding.

2. Patients with a history of allergies to the ingredients of this medication.

11、 Drug interactions

Anticoagulants (such as warfarin potassium) and antiplatelet drugs (such as aspirin): This product has an inhibitory effect on platelet aggregation and may promote bleeding. When used in combination, full observation and attention should be paid to side effects such as bleeding.

12、 Storage method

Room temperature storage, valid for 3 years.

13、 Manufacturer

Manufacturer and seller: Takeda Pharmaceutical Industry Co., Ltd. (1-1 Nihonbashimachi 2-chome, Chuo ku, Tokyo, Japan).

Lotrigainformation